Yedavally-Yellayi Srikala, Ho Andrew Manyin, Patalinghug Erwin Matthew
Department of Family Medicine, Family Medicine Residency Program, Beaumont Health Troy, 44250 Dequindre Road, Sterling Heights, MI 48314, USA; Oakland University William Beaumont School of Medicine, O'Dowd Hall, 586 Pioneer Drive, Rochester, MI 48309, USA.
Department of Family Medicine, Family Medicine Residency Program, Beaumont Health Troy, 44250 Dequindre Road, Sterling Heights, MI 48314, USA.
Prim Care. 2019 Mar;46(1):175-190. doi: 10.1016/j.pop.2018.10.014. Epub 2018 Dec 24.
Osteoporosis is often a silent disease that reveals itself at the time of a fracture. Assessing risk factors and applying appropriate screening guidelines in the population at risk can potentially decrease the looming high disease burden in the United States. FRAX is a validated tool that can be used to determine 10-year fracture risk to assist in medical decision making. Bone mineral density testing of the hip or spine using DEXA can be used alone or in combination with FRAX to determine patients' risk for fracture and determine if patients are candidates for treatment of osteoporosis.
骨质疏松症通常是一种隐匿性疾病，在骨折发生时才会显现出来。评估风险因素并对高危人群应用适当的筛查指南，有可能降低美国日益逼近的高疾病负担。FRAX是一种经过验证的工具，可用于确定10年骨折风险，以协助医疗决策。使用双能X线吸收法（DEXA）对髋部或脊柱进行骨密度检测，可单独使用或与FRAX联合使用，以确定患者的骨折风险，并确定患者是否为骨质疏松症治疗的候选对象。
